The Technical Analyst
SOPHiA GENETICS SA [SOPH]
Exchange: NASDAQ Sector: Healthcare Industry: Health Information Services
SOPHiA GENETICS SA Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.62% $5.03
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 328.47 mill |
| EPS: | -1.220 |
| P/E: | -4.12 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 65.30 mill |
| Avg Daily Volume: | 0.0593 mill |
| RATING 2024-04-26 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.12 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -4.12 | industry: PE -4.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 4.60 - 5.46 ( +/- 8.51%) |
| ATR Model: 14 days |
Forecast:
16:00 - $5.03
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $5.03
Forecast 2: 16:00 - $5.03
Forecast 3: 16:00 - $5.03
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $5.03 (1.62% ) |
| Volume | 0.0279 mill |
| Avg. Vol. | 0.0593 mill |
| % of Avg. Vol | 47.11 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SOPH
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SOPH
SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.
Latest Press Releases
2024-04-23 10:29:00 - Press Release
Sophia Genetics To Announce Financial Results For First Quarter 2024 On May 7, 2024
Boston and rolle, switzerland, april 23, 2024 (globe newswire) -- sophia genetics, a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter of fiscal year 2024 before u.s. markets open on tuesday, may 7, 2024. on that day, sophia genetics will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) edt / 2:00 p.m. (14:00) cet.
2024-04-23 05:05:00 - Press Release
Sophia Genetics Announces Syndicate Bio As First Liquid Biopsy Customer In Africa
Syndicate bio to implement new liquid biopsy offering to advance cancer diagnostics throughout africa boston and rolle, switzerland , april 23, 2024 /prnewswire/ -- sophia genetics (nasdaq: soph), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that nigeria-based syndicate bio has signed on to implement msk-access® powered with sophia ddm™ . syndicate bio is the first lab in africa to adopt the msk-access® assay via the sophia ddm™ platform, and the first company to make comprehensive genomic profiling and liquid biopsy widely available to patients throughout the entire continent.
2024-04-17 06:05:00 - Press Release
Sophia Genetics Announces Unilabs Is Using Its Ai Technology To Detect Homologous Recombination Deficiency (hrd)
European-based unilabs has deployed the sophia ddm™ platform across its network in switzerland to support cancer diagnostics and treatment boston and rolle, switzerland , april 17, 2024 /prnewswire/ -- sophia genetics (nasdaq: soph), a cloud-native software company and a leader in data-driven medicine, today announced that unilabs, one of the largest diagnostic providers in europe, and the only provider to offer laboratory, imaging and pathology specialties within one group, is live on the sophia ddm™ platform. unilabs will use sophia genetics' technology to test for hrd-status in solid tumors and provide expedited analysis across its network in switzerland.
2024-04-04 01:00:00 - Press Release
Sophia Genetics And Strand Life Sciences Announce New Strategic Partnership
The companies will join forces to advance the use of precision medicine on a global scale boston and rolle, switzerland , april 4, 2024 /prnewswire/ -- sophia genetics (nasdaq: soph), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced a strategic partnership with strand life sciences, a pioneer in bioinformatics and diagnostics, to deliver innovative solutions that will fuel the use of precision medicine globally. the new collaboration will leverage the industry-leading strengths from both companies to provide access to advanced genomics technologies, cutting-edge bioinformatics services and innovative diagnostics solutions.
2024-04-02 10:00:00 - Press Release
Laboratorio Barnafi-krause Is Live On Sophia Ddm™
The chile-based laboratory is using sophia genetics' platform to advance its research capabilities with blood disorders boston and rolle, switzerland , april 2, 2024 /prnewswire/ -- sophia genetics (nasdaq: soph), a cloud-native software company and a leader in data-driven medicine, today announced that laboratorio barnafi-krause is live on the sophia ddm™ platform. laboratorio barnafi-krause, located in chile, has implemented sophia genetics' technology to help elevate its testing and analysis of blood cancers and diseases, including leukemia.
Latest News
2024-04-23 10:29:00 - GlobeNewsWire
SOPHiA GENETICS to Announce Financial Results for First Quarter 2024 on May 7, 2024
BOSTON and ROLLE, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter of fiscal year 2024 before U.S. markets open on Tuesday, May 7, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET.
2024-03-07 12:07:00 - GlobeNewsWire
SOPHiA GENETICS to Present at the Barclays 26th Annual Global Healthcare Conference
BOSTON and ROLLE, Switzerland, March 07, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced Chief Financial Officer and Chief Operating Officer, Ross Muken, will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13, 2024, at 2:35 p.m. EDT.
2024-02-20 10:46:00 - GlobeNewsWire
SOPHiA GENETICS to Announce Financial Results for the Fourth Quarter and Full-Year 2023 on March 5, 2024
BOSTON and ROLLE, Switzerland, Feb. 20, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full-year 2023 before U.S. markets open on Tuesday, March 5, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m.
2023-11-11 16:22:05 - Seeking Alpha
SOPHiA GENETICS SA (SOPH) Q3 2023 Earnings Call Transcript
SOPHiA GENETICS SA (NASDAQ:SOPH ) Q3 2023 Results Conference Call November 7, 2023 8:00 AM ET Company Participants Katherine Bailon - Head, IR Dr. Jurgi Camblong - Co-Founder and CEO Ross Muken - CFO and COO Conference Call Participants Yuko Oku - Morgan Stanley Kyle Boucher - TD Cowen Mark Massaro - BTIG Operator Ladies and gentlemen, thank you for standing by. My name is Desiree and I will be your conference operator today.
2023-10-24 05:50:00 - GlobeNewsWire
SOPHiA GENETICS to Announce Financial Results for the Third Quarter of Fiscal 2023 on November 7, 2023
BOSTON and GENEVA, Switzerland, Oct. 24, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the third quarter of fiscal 2023 before U.S. markets open on Tuesday, November 7, 2023. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EST / 2:00 p.m. (14:00) CEST.
2023-08-12 12:24:07 - Seeking Alpha
SOPHiA GENETICS SA (SOPH) Q2 2023 Earnings Call Transcript
SOPHiA GENETICS SA (NASDAQ:SOPH ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Katherine Bailon - Head, Investor Relations Dr. Jurgi Camblong - Co-Founder and CEO Ross Muken - Chief Financial Officer and COO Conference Call Participants Edmund Tu - Morgan Stanley Dan Brennan - TD Cowen Rachel Vatnsdal - JPMorgan Vidyun Bais - BTIG Operator Hello, ladies and gentlemen. And thank you for joining SOPHiA GENETICS Second Quarter 2020 Earnings Call.
2023-08-08 09:55:51 - Zacks Investment Research
SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Misses Revenue Estimates
SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.39 per share a year ago.
2023-07-25 07:35:00 - PRNewsWire
SOPHiA GENETICS to Announce Financial Results for the Second Quarter of Fiscal 2023 on August 8, 2023
BOSTON and ROLLE, Switzerland , July 25, 2023 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced it will release its financial results for the second quarter of fiscal 2023 before U.S. markets open on Tuesday, August 8, 2023. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m.
2023-05-13 05:34:01 - Seeking Alpha
SOPHiA GENETICS SA (SOPH) Q1 2023 Earnings Call Transcript
SOPHiA GENETICS SA (NASDAQ:SOPH ) Q1 2023 Earnings Conference Call May 9, 2023 8:00 AM ET Company Participants Katherine Bailon - Vice President of Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer Ross Muken - Chief Financial Officer and Chief Operating Officer Conference Call Participants Tejas Savant - Morgan Stanley Marta Nazarovets - JPMorgan Chase & Co. Kyle Boucher - TD Cowen Operator Good morning, and welcome to the SOPHiA GENETICS' First Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode.
2023-04-25 07:11:00 - GlobeNewsWire
SOPHiA GENETICS to Announce Financial Results for the First Quarter of Fiscal 2023 on May 9, 2023
BOSTON and GENEVA, Switzerland, April 25, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced it will release its financial results for the first quarter of fiscal 2023 before U.S. markets open on Tuesday, May 9, 2023. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CEST.